#hepatocellular carcinoma

Checkpoint Immunotherapy Looks Promising for Operable Liver Cancer

Immunotherapy led to fewer side effects and better quality of life than standard-of-care therapy.

Karen Hoyt promised her grandkids she would win a gold medal in the World Transplant Games. She wasn’t going to let HCC stand in her way.

Phase III study misses statistical threshold, but the immunotherapy appears to show some benefit.

Even positive breaking news looks different to people who know the reality of a hard-to-treat cancer.

Study in China sees an association with several cancer types, especially gastrointestinal malignancies.

Keytruda showed modest benefits for people with this difficult-to-treat cancer, and combining Opdivo with Yervoy improved outcomes.

There are now five targeted therapies for the most common type of liver cancer.

Do you know your liver cancer risk?

Tenofovir was associated with a lower risk of hepatocellular carcinoma, but this might be related to other factors as well.

People who took Viread were about two thirds less likely to develop HCC, but this could be related to other factors as well.

Keytruda and Opdivo showed antitumor activity in some patients and acceptable side effects in real-world use.

Study finds that having more diverse gut bacteria was associated with better response to immunotherapy.

Cabometyx is the third liver cancer drug approved in the past six months.

People with HIV who have higher viral load and worse immune function appear to be at higher risk for hepatocellular carcinoma.

A study found that people who had the largest increase in whole grain lowered their liver cancer risk by nearly 40 percent.

Seventy percent of liver cancer patients had either a partial response or stable disease.